Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation

Kaoru Okishige, Yasuteru Yamauchi, Yuichi Hanaki, Koichi Inoue, Nobuaki Tanaka, Hirosuke Yamaji, Takashi Murakami, Mamoru Manita, Kazuhiro Tabata, Tatsuhiko Ooie, Youichi Tatsukawa, Hirotsuka Sakai, Masaru Yamaki, Masato Murakami, Takuma Takada, Yuki Osaka, Yuichi Ono, Keita Handa, Koji Sugiyama, Tomoharu YoshizawaHidehira Fukaya, Hideki Tashiro, Susumu Takase, Masahide Harada, Eiichi Watanabe, Teiichi Yamane, Seigo Yamashita, Kazutaka Aonuma

Research output: Contribution to journalArticle

Abstract

Anticoagulants are prescribed for prevention of thromboembolic events (TE) of atrial fibrillation (AF), however, their effects have a negative impact on disastrous bleeding outcomes. Idarucizumab was developed to reverse the anticoagulation effects of dabigatran. This study aimed to retrospectively investigate the clinical efficacy and safety of idarucizumab in the setting of progressive emergent bleeding events associated with catheter ablation (CA). Dabigatran is given uninterruptedly as an anticoagulant in patients undergoing CA of AF. The capacity of idarucizumab to reverse the anticoagulant effects of dabigatran in patients with cardiac tamponade associated with CA was examined by measuring the activated partial thromboplastin time (aPTT), active clotting time (ACT), and prothrombin international normalizing ratio (PT-INR). The primary endpoint was effective hemostasis. This analysis included 21 patients receiving idarucizumab, given for restoration of hemostasis. In all 21 patients, hemostasis was restored at a median of 205.6 ± 14.8 min. Normal intraoperative cessation of bleeding was reported in 16 patients, and completion of hemostasis was also ascertained in the remaining four within 5 h. No TEs occurred within 72 h after the idarucizumab administration. Despite a significant reduction in the aPTT and ACT, no significant change was observed in PT-INR after administering idarucizumab. In emergency situations, idarucizumab was able to reverse dabigatran within a relatively short period without any serious adverse events.

Original languageEnglish
Pages (from-to)487-494
Number of pages8
JournalJournal of Thrombosis and Thrombolysis
Volume47
Issue number4
DOIs
Publication statusPublished - 15-05-2019

Fingerprint

Cardiac Tamponade
Catheter Ablation
Atrial Fibrillation
Hemostasis
Anticoagulants
Partial Thromboplastin Time
Hemorrhage
Prothrombin Time
Prothrombin
idarucizumab
Dabigatran
Emergencies
Safety

All Science Journal Classification (ASJC) codes

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

Okishige, Kaoru ; Yamauchi, Yasuteru ; Hanaki, Yuichi ; Inoue, Koichi ; Tanaka, Nobuaki ; Yamaji, Hirosuke ; Murakami, Takashi ; Manita, Mamoru ; Tabata, Kazuhiro ; Ooie, Tatsuhiko ; Tatsukawa, Youichi ; Sakai, Hirotsuka ; Yamaki, Masaru ; Murakami, Masato ; Takada, Takuma ; Osaka, Yuki ; Ono, Yuichi ; Handa, Keita ; Sugiyama, Koji ; Yoshizawa, Tomoharu ; Fukaya, Hidehira ; Tashiro, Hideki ; Takase, Susumu ; Harada, Masahide ; Watanabe, Eiichi ; Yamane, Teiichi ; Yamashita, Seigo ; Aonuma, Kazutaka. / Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation. In: Journal of Thrombosis and Thrombolysis. 2019 ; Vol. 47, No. 4. pp. 487-494.
@article{52bc588f74a3454fa257afb190ac3b5b,
title = "Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation",
abstract = "Anticoagulants are prescribed for prevention of thromboembolic events (TE) of atrial fibrillation (AF), however, their effects have a negative impact on disastrous bleeding outcomes. Idarucizumab was developed to reverse the anticoagulation effects of dabigatran. This study aimed to retrospectively investigate the clinical efficacy and safety of idarucizumab in the setting of progressive emergent bleeding events associated with catheter ablation (CA). Dabigatran is given uninterruptedly as an anticoagulant in patients undergoing CA of AF. The capacity of idarucizumab to reverse the anticoagulant effects of dabigatran in patients with cardiac tamponade associated with CA was examined by measuring the activated partial thromboplastin time (aPTT), active clotting time (ACT), and prothrombin international normalizing ratio (PT-INR). The primary endpoint was effective hemostasis. This analysis included 21 patients receiving idarucizumab, given for restoration of hemostasis. In all 21 patients, hemostasis was restored at a median of 205.6 ± 14.8 min. Normal intraoperative cessation of bleeding was reported in 16 patients, and completion of hemostasis was also ascertained in the remaining four within 5 h. No TEs occurred within 72 h after the idarucizumab administration. Despite a significant reduction in the aPTT and ACT, no significant change was observed in PT-INR after administering idarucizumab. In emergency situations, idarucizumab was able to reverse dabigatran within a relatively short period without any serious adverse events.",
author = "Kaoru Okishige and Yasuteru Yamauchi and Yuichi Hanaki and Koichi Inoue and Nobuaki Tanaka and Hirosuke Yamaji and Takashi Murakami and Mamoru Manita and Kazuhiro Tabata and Tatsuhiko Ooie and Youichi Tatsukawa and Hirotsuka Sakai and Masaru Yamaki and Masato Murakami and Takuma Takada and Yuki Osaka and Yuichi Ono and Keita Handa and Koji Sugiyama and Tomoharu Yoshizawa and Hidehira Fukaya and Hideki Tashiro and Susumu Takase and Masahide Harada and Eiichi Watanabe and Teiichi Yamane and Seigo Yamashita and Kazutaka Aonuma",
year = "2019",
month = "5",
day = "15",
doi = "10.1007/s11239-019-01835-8",
language = "English",
volume = "47",
pages = "487--494",
journal = "Journal of Thrombosis and Thrombolysis",
issn = "0929-5305",
publisher = "Springer Netherlands",
number = "4",

}

Okishige, K, Yamauchi, Y, Hanaki, Y, Inoue, K, Tanaka, N, Yamaji, H, Murakami, T, Manita, M, Tabata, K, Ooie, T, Tatsukawa, Y, Sakai, H, Yamaki, M, Murakami, M, Takada, T, Osaka, Y, Ono, Y, Handa, K, Sugiyama, K, Yoshizawa, T, Fukaya, H, Tashiro, H, Takase, S, Harada, M, Watanabe, E, Yamane, T, Yamashita, S & Aonuma, K 2019, 'Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation', Journal of Thrombosis and Thrombolysis, vol. 47, no. 4, pp. 487-494. https://doi.org/10.1007/s11239-019-01835-8

Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation. / Okishige, Kaoru; Yamauchi, Yasuteru; Hanaki, Yuichi; Inoue, Koichi; Tanaka, Nobuaki; Yamaji, Hirosuke; Murakami, Takashi; Manita, Mamoru; Tabata, Kazuhiro; Ooie, Tatsuhiko; Tatsukawa, Youichi; Sakai, Hirotsuka; Yamaki, Masaru; Murakami, Masato; Takada, Takuma; Osaka, Yuki; Ono, Yuichi; Handa, Keita; Sugiyama, Koji; Yoshizawa, Tomoharu; Fukaya, Hidehira; Tashiro, Hideki; Takase, Susumu; Harada, Masahide; Watanabe, Eiichi; Yamane, Teiichi; Yamashita, Seigo; Aonuma, Kazutaka.

In: Journal of Thrombosis and Thrombolysis, Vol. 47, No. 4, 15.05.2019, p. 487-494.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation

AU - Okishige, Kaoru

AU - Yamauchi, Yasuteru

AU - Hanaki, Yuichi

AU - Inoue, Koichi

AU - Tanaka, Nobuaki

AU - Yamaji, Hirosuke

AU - Murakami, Takashi

AU - Manita, Mamoru

AU - Tabata, Kazuhiro

AU - Ooie, Tatsuhiko

AU - Tatsukawa, Youichi

AU - Sakai, Hirotsuka

AU - Yamaki, Masaru

AU - Murakami, Masato

AU - Takada, Takuma

AU - Osaka, Yuki

AU - Ono, Yuichi

AU - Handa, Keita

AU - Sugiyama, Koji

AU - Yoshizawa, Tomoharu

AU - Fukaya, Hidehira

AU - Tashiro, Hideki

AU - Takase, Susumu

AU - Harada, Masahide

AU - Watanabe, Eiichi

AU - Yamane, Teiichi

AU - Yamashita, Seigo

AU - Aonuma, Kazutaka

PY - 2019/5/15

Y1 - 2019/5/15

N2 - Anticoagulants are prescribed for prevention of thromboembolic events (TE) of atrial fibrillation (AF), however, their effects have a negative impact on disastrous bleeding outcomes. Idarucizumab was developed to reverse the anticoagulation effects of dabigatran. This study aimed to retrospectively investigate the clinical efficacy and safety of idarucizumab in the setting of progressive emergent bleeding events associated with catheter ablation (CA). Dabigatran is given uninterruptedly as an anticoagulant in patients undergoing CA of AF. The capacity of idarucizumab to reverse the anticoagulant effects of dabigatran in patients with cardiac tamponade associated with CA was examined by measuring the activated partial thromboplastin time (aPTT), active clotting time (ACT), and prothrombin international normalizing ratio (PT-INR). The primary endpoint was effective hemostasis. This analysis included 21 patients receiving idarucizumab, given for restoration of hemostasis. In all 21 patients, hemostasis was restored at a median of 205.6 ± 14.8 min. Normal intraoperative cessation of bleeding was reported in 16 patients, and completion of hemostasis was also ascertained in the remaining four within 5 h. No TEs occurred within 72 h after the idarucizumab administration. Despite a significant reduction in the aPTT and ACT, no significant change was observed in PT-INR after administering idarucizumab. In emergency situations, idarucizumab was able to reverse dabigatran within a relatively short period without any serious adverse events.

AB - Anticoagulants are prescribed for prevention of thromboembolic events (TE) of atrial fibrillation (AF), however, their effects have a negative impact on disastrous bleeding outcomes. Idarucizumab was developed to reverse the anticoagulation effects of dabigatran. This study aimed to retrospectively investigate the clinical efficacy and safety of idarucizumab in the setting of progressive emergent bleeding events associated with catheter ablation (CA). Dabigatran is given uninterruptedly as an anticoagulant in patients undergoing CA of AF. The capacity of idarucizumab to reverse the anticoagulant effects of dabigatran in patients with cardiac tamponade associated with CA was examined by measuring the activated partial thromboplastin time (aPTT), active clotting time (ACT), and prothrombin international normalizing ratio (PT-INR). The primary endpoint was effective hemostasis. This analysis included 21 patients receiving idarucizumab, given for restoration of hemostasis. In all 21 patients, hemostasis was restored at a median of 205.6 ± 14.8 min. Normal intraoperative cessation of bleeding was reported in 16 patients, and completion of hemostasis was also ascertained in the remaining four within 5 h. No TEs occurred within 72 h after the idarucizumab administration. Despite a significant reduction in the aPTT and ACT, no significant change was observed in PT-INR after administering idarucizumab. In emergency situations, idarucizumab was able to reverse dabigatran within a relatively short period without any serious adverse events.

UR - http://www.scopus.com/inward/record.url?scp=85064767602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064767602&partnerID=8YFLogxK

U2 - 10.1007/s11239-019-01835-8

DO - 10.1007/s11239-019-01835-8

M3 - Article

C2 - 30955142

AN - SCOPUS:85064767602

VL - 47

SP - 487

EP - 494

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

SN - 0929-5305

IS - 4

ER -